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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The primary objective will be to evaluate the eJicacy and harms of the interventions for the treatment of iron deficiency anaemia in people
with inflammatory bowel disease and rank the treatments in order of eJectiveness in a network meta-analysis.
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B A C K G R O U N D
Description of the condition
Anaemia in people with inflammatory bowel disease is an
extraintestinal manifestation that historically has received little
attention compared with other extraintestinal diseases such as
arthritis or osteoarthritis (Stein 2012). Iron deficiency anaemia is
a significant and common systemic manifestation of inflammatory
bowel disease. Iron deficiency anaemia manifests as fatigue,
shortness of breath, heart palpitations and pale skin (Niepel
2018). It significantly impacts on the quality of life of a person
with inflammatory bowel disease and on the progression of their
disease. Anaemia should not be accepted as an unavoidable
manifestation of inflammatory bowel disease. Prompt diagnosis
and eJective management is paramount.
There are two predominant types of anaemia that have been
identified and associated with inflammatory bowel disease, iron
deficiency anaemia and anaemia of chronic disease. The cause of
iron deficiency anaemia is multi-factorial; causes include, chronic
blood loss, malnutrition and haemolysis (Wilson 2004). Folic acid
deficiency is not an uncommon finding in these patients and the
administration of bone marrow-suppressing medications can also
aJect erythropoiesis.
Studies have reported the prevalence of iron deficiency anaemia
in people with inflammatory bowel disease to be as high as 36%
to 90% (Kulnigg 2006). The wide range of prevalence fits with
the fact that anaemia oMen mirrors disease activity in people
with inflammatory bowel disease. Interestingly prevalence is lower
in inflammatory bowel disease outpatients (Gomollon 2009),
occurring in 10% and 6% of Crohn's disease and ulcerative colitis
outpatients respectively (Antunes 2015), likely reflecting that this
population have lower rates of active disease and lower severity
of activity disease. Iron deficiency anaemia appears to be more
common in children (88%) than adults (55%) with inflammatory
bowel disease (Goodhand 2012).
Iron deficiency is the main cause of anaemia in inflammatory bowel
disease (Gomollon 2009), oMen as a result of dietary restrictions,
malabsorption, active bleeding and under-treatment of anaemia.
In addition, chronic abdominal pain and nausea oMen results in
poor oral intake, and mucosal inflammation in the gastrointestinal
tract can lead to inadequate nutrient absorption. Although iron
absorption tends to be normal in people with inflammatory bowel
disease, the iron loss may exceed the capacity for iron absorption
(Wilson 2004). This explains why activity levels of inflammatory
bowel disease correlate with levels of iron deficiency anaemia.
Anaemia has a significant eJect on the quality of life of people
with inflammatory bowel disease, even if it is not noticeably
symptomatic. Therefore it is important that anaemia is treated
eJectively and it should not be assumed that some element
of anaemia is a normal finding of inflammatory bowel disease
(Gomollon 2009). The World Health Organization's definitions
of anaemia apply to people with inflammatory bowel disease.
It is thought that people with inflammatory bowel disease
without anaemia but with iron deficiency should be considered
for treatment as it is of clinical relevance. Achieving normal
haemoglobin levels does not necessarily mean that normal iron
store levels have been restored.
Description of the intervention
There are various ways of treating iron deficiency anaemia and
administering iron, however the most eJective way in people
with inflammatory bowel disease remains unclear. Iron can
be administered orally, via intramuscular injection, intravenous
infusion and it is also possible to deliver iron via blood transfusion
or by using erythropoietin with iron. All of these routes require
consideration and likely need consideration of some of the
disease factors discussed above. This includes severity or activity
levels of disease at the time of therapy initiation, with active
disease potentially impacted by the eJicacy or tolerability of oral
interventions. Conversely, as both people with ulcerative colitis and
Crohn's disease follow a similar pathophysiological route to iron
deficiency anaemia (Wilson 2004), the specific disease type is likely
less of a factor than in most other areas of inflammatory bowel
disease management. Evidence has suggested that oral iron can
cause gastrointestinal disturbances and irritation (Tolkien 2015),
which may impact compliance. Intramuscular and intravenous
preparations have been associated with allergic reactions and
anaphylaxis (Akhuemonkhan 2018), as well as having diJerent
feasibility and practical considerations related to the need to
deliver these either within a healthcare environment or by a
healthcare professional. Blood transfusion carries the risk of
transmitting infections including viral and parasitic infections.
Historically oral administration of iron has been the preferred route
especially for mild anaemia, and intravenous and intramuscular
preparations have usually been reserved for more severe cases,
where the benefit of treatment is thought to outweigh the
associated risks and complications. Oral iron is inexpensive,
however it is thought to have short-term eJectiveness (Lee 2012).
On the other hand, intravenous iron therapy requires more complex
infrastructure and expertise to be administered. There are also
variations on doses and preparations used and frequency of
administration. The eJectiveness and appropriateness of any iron
therapy may depend on one or a combination factors for any given
patient, such as previous reaction to the treatment, the severity
of iron deficiency anaemia, disease activity or the use of adjunct
therapy, such as erythropoiesis stimulating agents (Stein 2013).
How the intervention might work
The eJicacy of intravenous iron therapy in people with
inflammatory bowel disease has been the topic of recent
investigation. Intravenous iron preparations that have been used
include iron gluconate, iron sucrose, iron dextran, ferumoxytol and
iron carboxymaltose. Iron dextran was the first parenteral iron
formulation approved by the US Food and Drug Administration
(FDA), however anaphylaxis has limited its use (Hassan 2011).
Ferumoxytol was FDA-approved in 2009. It possesses low antigenic
properties, so no test dose is required. The drug is phagocytosed
by macrophages and slowly released into the circulation, which
allows for rapid infusion in large doses (Hassan 2011). However no
data exist regarding dosing or safety in children and adolescents.
Proinflammatory cytokines are produced in increased amounts by
peripheral-blood monocytes in people with inflammatory bowel
disease (Schreiber 1996). Such cytokines can contribute to the
development of anaemia by inducing a relative deficiency of
erythropoietin (Schreiber 1996). It is thought that administering
erythropoietin could be beneficial for people with inflammatory
bowel disease; positive results have been observed in people
with rheumatoid arthritis and chronic renal failure with associated
anaemia (Gasche 1997; Schreiber 1996). Although recombinant
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human erythropoietin has been shown to be eJective for treating
anaemia that accompanies several chronic diseases (Goodnough
2000), it is costly and its benefits have not been shown to be
greatly superior to other iron preparations. However, it has been
suggested that its therapeutic potency can be maximised with
co-administration of other intravenous iron preparations (Gasche
1997).
Why it is important to do this review
The most eJective way of treating anaemia in people with
inflammatory bowel disease remains unclear. There is little
evidence to suggest that high doses of oral iron is beneficial. Only
10 mg to 20 mg of oral iron can be absorbed per day, therefore high
doses of oral iron of up to 400 mg per day remains questionable
(Gomollon 2009). With this rationale, a single tablet of most ferrous
salt preparations such as ferrous sulphate provides more iron than
can be absorbed. Additionally, non-absorbed iron salts can be toxic
to intestinal mucosa (Kawai 1992), and there have been concerns
that this can worsen disease activity or even activate disease.
High doses of oral iron can also induce diarrhoea which, as well
as impacting on quality of life can make distinguishing it from
actual disease relapse problematic. This has necessitated the use
of alternatives (Erichsen 2005; Lee 2017). These adverse events and
tolerability issues are of interest to people with inflammatory bowel
disease in general when considering options for therapy, but may
be particular important in subgroups such as children and young
people. In these groups acceptability can figure highly in decision
making by families.
Evidently there are a range of diJerent interventions that can be
utilised in order to combat the problem of iron deficiency anaemia
in people with inflammatory bowel disease. However, the eJicacy
and safety of each intervention remains poorly understood and
currently no consensus has been reached amongst physicians as to
which intervention is most beneficial. The European Crohn's and
Colitis Organisation (ECCO) guideline recommends intravenous
iron as first-line treatment in people with clinically active disease
with previous intolerance to oral iron who need erythropoiesis
stimulating agents (ECCO 2015). However, this recommendation is
not based on systematic review evidence, but rather on a pragmatic
consideration of these therapies for such patients. Given the range
of methods for delivering iron and treating iron deficiency anaemia
that clinicians and patients can choose from currently, we will
employ a network meta-analysis approach for this review. This will
allow ranking of therapies by both eJectiveness and side-eJect
profiles; both key relative factors used to guide decision making
from this portfolio of options.
For this reason we have identified a need for a Cochrane systematic
review to be carried out in order to methodically evaluate and
summarise the eJicacy and safety of the interventions available
for the treatment of iron deficiency anaemia in people with
inflammatory bowel disease. We will look primarily at how the
interventions aJect the haemoglobin levels in the participants
observed. We will also analyse how these interventions aJect
markers of iron stores, including transferrin saturation and serum
ferritin levels, and also the changes in disease activity and the
changes in reported quality of life.
O B J E C T I V E S
The primary objective will be to evaluate the eJicacy and harms of
the interventions for the treatment of iron deficiency anaemia in
people with inflammatory bowel disease and rank the treatments
in order of eJectiveness in a network meta-analysis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Published and unpublished randomised controlled trials (RCTs)
irrespective of language or year of publication. We will exclude
studies that used quasi-random methods in allocating participants
(e.g. date of birth). We will only include cross-over RCTs if data are
reported for the first treatment phase prior to cross-over. We do not
anticipate finding any cluster-RCTs, but we will include cluster-RCTs
if available.
Types of participants
People of any age and sex with a conventional diagnosis of Crohn's
disease, ulcerative colitis or indeterminate colitis with confirmed
iron deficiency anaemia as defined by the authors of the primary
studies. Potential eJect modifiers identified were age and disease
activity. Therefore we will only assume that there is transitivity
within specific age group and disease activity. For instance, adult
with active disease, adult with inactive disease, etc.
Types of interventions
The administration of iron therapy by any route (e.g. orally,
intramuscularly, intravenously, subcutaneously) for the treatment
of iron deficiency anaemia. We will compare these interventions
with control, placebo, no intervention or other interventions.
Types of outcome measures
Where possible we plan to collect data on the following outcomes.
Primary outcomes
Response (defined as the number of people with normalisation
of haemoglobin levels or increase of haemoglobin at the end of
treatment course). This definition is based on a previous systematic
review by Aksan 2017, as well as scoping of the wider literature.
Secondary outcomes
• Time to response (survival data reported as a hazard ratio (HR)
with standard error (SE))
• Change in haemoglobin levels
• Tolerability of treatment
• Non-compliance with treatment regimen
• Adverse events (such as constipation, abdominal pain, nausea,
etc)
• Serious adverse events
• Withdrawal due to adverse events
• Health-related quality of life (measured using Inflammatory
Bowel Disease Questionnaire (IBDQ) (Irvine 1994), Short IBDQ
(SIBDQ) (Irvine 1996) or any other validated scale)
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We will note where outcome data are available for multiple time
points, however we will only report outcome measures at the last
time point available. We intend to produce network diagrams to
show the amount of evidence for all selected studies contributing
data to 'response' and 'withdrawal due to adverse events' and rank
the interventions based on these outcomes.
Search methods for identification of studies
Electronic searches
We will search the following sources from inception of each
database to the date of search and will place no restrictions on the
language of publication:
• Cochrane Central Register of Controlled Trials (CENTRAL) via
Ovid Evidence-Based Medicine Reviews Database (EBMR);
• MEDLINE (Ovid MEDLINE ALL 1946 to Daily Update);
• CINAHL EBSCO (Cumulative Index to Nursing and Allied Health
Literature);
• ClinicalTrials.gov (www.clinicaltrials.gov);
• World Health Organization International Clinical Trials Registry
Platform (ICTRP; www.who.int/trialsearch/).
For detailed search strategies, see Appendix 1. We will adapt
this search strategy and use it to search the proposed electronic
databases. There is evidence to suggest that data from abstracts
can be inconsistent with data published in articles (Pitkin 1999).
Searching other resources
• Reference searching: we will inspect the references of all
identified studies for more relevant papers.
• Personal contacts: we will contact leaders in the field to identify
other studies.
• Drug companies: we will contact manufacturers of appropriate
iron preparations for additional information.
Data collection and analysis
Selection of studies
Using the above search strategy, two review authors will
independently identify studies that appear to be potentially
relevant. The two review authors will independently read the
full texts to assess the eligibility of the papers identified. AMer
reading the full texts, the two review authors will independently
assess the eligibility of all studies identified based on the inclusion
criteria above. Disagreement among reviewers will be discussed
and agreement reached by consensus. We will implement this
process in order to reduce the risk of bias and decrease the chances
of any inaccuracies during the interpretation of the studies.
Data extraction and management
We will develop a data extraction form and use it to extract
information on relevant features and results of the included
studies. The two review authors will extract and record data on the
predefined data extraction form, independently and in duplicate.
Extracted data will include the following items:
• characteristics of participants: age, sex, disease distribution,
disease duration, disease type and disease activity index;
• total number of participants originally assigned to each
intervention group;
• intervention: type and dose; mode of administration;
• control: no intervention, placebo or other interventions;
• concurrent medications
• outcomes: time of assessment, length of follow-up, change in
haemoglobin status, change in transferrin saturation, changes in
serum ferritin levels, quality-of-life assessment, adverse events.
Assessment of risk of bias in included studies
Two review authors will independently assess bias using the
Cochrane 'Risk of bias' tool (Higgins 2017). Since our review will
only focus on data from the first treatment period before cross-over,
'Risk of bias' assessment for any cross-over trials identified will be
the same as the parallel-group trials. For the cluster-RCTs, we will
assess risk of bias following guidance listed in Table 23.1.a of the
Cochrane Handbook for Systematic Reviews of Interventions (Higigns
2019). The study features to be assessed include:
• random sequence generation;
• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• completeness of outcome data;
• selective reporting; and
• other sources of bias.
We will rate each of these factors as ‘low risk’, ‘high risk’ or ‘unclear
risk’ of bias. AMer we have assessed risk of bias at study level, we will
then use the CINeMA (Confidence in Network Meta-Analysis) web
tool to calculate the percentage contribution of each direct contrast
to each network estimate (CINeMA 2017).
Measures of treatment e8ect
We will calculate the risk ratio (RR) for dichotomous outcomes. We
will report time-to-response data as hazard ratios (HR). However,
where studies report mean response time, we will calculate
mean diJerence (MD), provided that the studies indicate that all
participants responded to treatment during the trial period. If the
studies assess health-related quality-of-life data using diJerent
scales, we will estimate the treatment eJect using the standardised
mean diJerence (SMD). We will present SMDs as standard deviation
units and interpret as follows: 0.2 represents a small eJect, 0.5
a moderate eJect and 0.8 a large eJect (Cohen 1988). We will
report these measures of treatment eJects alongside associated
95% confidence intervals (CI).
Unit of analysis issues
If we include cross-over trials, we will extract data from the
first phase of the study for analysis (i.e. before the cross over
occurred). We will conduct separate analyses for comparisons
between iron intervention versus placebo, and irons versus
active comparator (e.g. alternative iron intervention). If studies
randomised participants to more than one iron treatment arm
(e.g. with diJerent doses), we will combine these for the primary
analysis. Where outcomes are reported at several time points, we
will undertake analyses at a single time point that is consistently
reported by the studies and at the final point of follow-up. Where
network meta-analyses are conducted, we will account for the
eJects of correlated eJect estimates using appropriate methods
(see Data synthesis).
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Dealing with missing data
We will contact the authors of included studies to supply any
missing data. If data are needed to judge the risk of bias, we will
make a judgement of unclear risk in the relevant category. Where
'response' outcome data are missing, we will use the intention-to-
treat principle (ITT) on the assumption that all participants lost to
follow-up were non-responders.
Assessment of heterogeneity
We will assess heterogeneity and inconsistency to ensure the
validity of the analysis. Initially, we will assess heterogeneity
through visual inspection of forest plots and the calculation of
the Chi2 and I2 statistics (Borenstein 2009). For the network
meta-analyses, we will use the between-study standard deviation
to assess heterogeneity, with a threshold of 0.5 indicating
heterogeneity. We will interpret I2 statistics according to the guide
below (Deeks 2019):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
We will assess consistency within the analysis through comparison
of the estimates of treatment eJect for each comparison from the
direct and indirect pairwise meta-analyses for the closed loops
within the NMA, using a node-splitting approach (Cooper 2009;
Dias 2000). It is important that the direct and indirect evidence for
the same comparisons agree, as joint analysis on an inconsistent
network can be misleading. We will examine possible explanations
for heterogeneity where suJicient data are available, including
factors such as participant characteristics (e.g. age, sex), condition
severity, treatment type and dose, healthcare system, and country.
Assessment of reporting biases
If there is an appropriate number of studies in a pooled analysis (i.e.
more than 10 studies), we plan to investigate potential publication
bias using funnel plots: trial eJects versus trial size (Sterne 2017).
Data synthesis
We will synthesise studies through a narrative review with
tabulation of results of included studies. Where possible, we will
synthesise treatment eJects for all comparisons and outcomes
through meta-analyses, with the approach taken dependant on the
outcome assessed and the data available (Borenstein 2009). We will
conduct direct comparisons of treatment eJects through pairwise
meta-analyses. For the pairwise meta-analysis, we will analyse
studies that are clinically homogeneous in terms of population,
intervention, comparator and outcome. We will analyse studies
that include ulcerative colitis, Crohn's disease or mixed populations
together. However, we will analyse studies of diJerent disease
states (active, inactive) separately, and studies from paediatric
population separately from adult data. We will use the fixed-
eJect model to carry out meta-analysis of primary and secondary
outcome measures when we judge clinical and methodological
heterogeneity to be appropriately low (I2 = 0%).
Second, where possible, we will assess the opportunity for
estimating a network meta-analysis to compare diJerent
interventions through both direct and indirect evidence within
connected networks of studies (Spiegelhalter 2004; Welton 2012).
We will carry out network meta-analyses for the 'response' and
'withdrawal due to adverse events' outcomes. The use of direct
and indirect evidence can strengthen inferences about the relative
eJicacy of the interventions being compared, whether due to a
lack of, or sparse, evidence comparing the diJerent interventions.
Importantly, network meta-analyses allow for the comparison of
multiple interventions simultaneously and for an estimation of the
rank order based on eJicacy (Welton 2012). We will present the
network for the models graphically through network diagrams,
allowing assessment of both the structure and extent of the
evidence available for the diJerent comparisons.
All network meta-analyses will take a Bayesian approach through
Markov Chain Monte Carlo (MCMC) simulation (Chaimani 2019).
The parameters that we will consider in the models will be
the treatment eJect of an intervention compared with other
interventions, with the likelihood function dependent on the
outcome used. We will assume study-specific log-odds ratios (ORs)
to be from the normal distribution. We will use diJerent prior
distributions for the scale parameters (e.g. a uniform distribution
for the base case and half-normal and inverse gamma distributions
for sensitivity analyses). We will use vague priors for the treatment
eJects in the diJerent models and we will estimate all models using
three chains starting with diJerent initial values. We will assess
convergence through visual inspection of the Brooks-Gelman-
Rubin diagnostic, with convergence assumed to have occurred
when the ratio of between- and within-chain variability is stable
around 1. We will use varying iterations and burn-in periods to
ensure convergence, with burn-in periods discarded from the
analysis. We will examine autocorrelation plots, with diJerent rates
of thinning applied to eliminate or reduce its eJects where present.
From each MCMC run, we will rank the treatments based on the
magnitude of eJect. We will then estimate the cumulative rank
probabilities from the proportion of MCMC cycles in which each
treatment has a certain rank. We will summarise the ranking in
mean and range and display ranking in graphs. The closer the mean
rank is to 1, the better the eJicacy or safety.
We will assess adequacy of the fit of the models through a
comparison of the residual deviance for the models with the
number of unconstrained data points available, with an adequate
fit when both closely match. Model selection and overall goodness
of fit will be assessed through deviance information criteria (DIC),
with a threshold of a diJerence of 3 to 5 points considered
significant (lowest DIC = most appropriate fit; Spiegelhalter 2002,
Welton 2012).
We will conduct pairwise meta-analyses of direct comparisons
using Review Manager 5 (RevMan 5 (Review Manager 2014)), and
Stata (Deeks 2019; Egger 2001), while we will estimate NMAs using
the WinBUGS soMware.
Subgroup analysis and investigation of heterogeneity
As already noted, where heterogeneity is identified, we will
investigate its possible causes through the inclusion of patient-
and study-level characteristics as covariate within meta-regression
analyses. The meta-regression will include factors such as length
of follow-up, adopting the approach outlined by Achana and
colleagues (Achana 2013). As the primary outcome (i.e. response)
represents the number of events that occur within a patient
population allocated to a particular treatment, we will assume a
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binomial distribution for the likelihood and we will use a clog-log
link in the NMA for the linear predictor to take time into account.
To carry out a statistical assessment of the disagreement between
estimates within each pairwise comparison, we plan to use the I2
statistic (Deeks 2019). We will also visually assess the overlap of the
confidence intervals with the prediction interval and the variability
in the point estimates. We will interpret I2 statistic thresholds as
follows:
• less than 50% will be regarded as low;
• 50% to 75% will be regarded as moderate; and
• more than 75% will be regarded as large.
Assessment of statistical inconsistency
We will also assess whether there is disagreement between direct
and indirect estimates or between indirect estimates through
diJerent intermediate treatments in the network. We will do this
for single loops of evidence within the network and for the network
as a whole (Dias 2013; Salanti 2014). If suJicient data are available
we will perform subgroup analysis to assess the impact of length of
follow-up using methods described above
Sensitivity analysis
For the pairwise analysis of the primary outcome, we will conduct
sensitivity analyses based on the following:
• random-eJect versus fixed-eJect modelling;
• excluding studies assessed as unclear or high risk of bias
according to the Cochrane 'Risk of bias' tool;
• only including participants whose outcome is known (i.e.
number of participants who completed the study used as a
denominator).
Summary of findings and assessment of the certainty of the
evidence
Assessment of evidence certainty generated from the network meta-
analysis
We will assess the certainty of the evidence using GRADE (Chaimani
2019; Schünemann 2019a; Schünemann 2019b). We will apply this
methodology to the network meta-analysis by focusing on the
approach of Salanti 2014. This will be carried out using GRADEpro
GDT and the CINeMA web tool (CINeMA 2017), where possible.
We will assess evidence quality in two main ways, firstly, for each
contrast and secondly, for the network as a whole, in order to assess
the quality of the ranking order. We will assess individual GRADE
factors as follows.
• Risk of bias: we will assess overall risk of bias for each contrast
and also for the entire network.
• Indirectness: this relates to whether the population,
intervention and outcome in the studies diJer from those we
have proposed (see Criteria for considering studies for this
review) as well as intransitivity.
• Inconsistency: at the level of the contrast, we will take into
consideration both heterogeneity in the direct evidence for that
comparison and inconsistency related to diJerent routes of
analysis for the comparison (e.g. direct versus indirect evidence
and two-arm versus three-arm trials). We will conduct the latter
using a node-splitting approach (Dias 2013). As well as assessing
the meta-analyses of the direct evidence for inconsistency, we
will consider the network meta-analysis predictive intervals
for that comparison in relation to GRADE 'default' minimum
important diJerences, 0.75 and 1.25 (Guyatt 2011). We note that
inconsistency can only be assessed where there is both direct
and indirect evidence. We will assess GRADE inconsistency as
serious limitations if there is heterogeneity in the direct estimate
or inconsistency in the network with respect to that comparison.
We will attribute very serious limitations to the comparison
if there is severe heterogeneity or severe inconsistency or
limitations with both heterogeneity and inconsistency. We will
determine judgements on the magnitude of limitations by the
reviewers through discussions. Rationales will be described
transparently in the review report. At the level of the network,
we will consider the global Wald test for inconsistency. Tests of
this nature are typically underpowered, so a P value less than 0.1
will be considered significant. Additionally, if several contrasts
show direct and indirect results that would have led to diJerent
clinical decisions, we will consider inconsistency to be present.
• Imprecision: at the level of the contrast, we will assess
inconsistency for each pairwise comparison using the GRADE
default minimally important diJerence values of 1.25 and 0.75
for the RR. We will also take into account the sample size for
the direct evidence informing this contrast and consider it in
relation to the optimal information size. At the level of the
network, we will assess the overlap of the rankograms and the
magnitude of the surface under the cumulative ranking (SUCRA)
curve estimates.
• Publication bias: we will also assessed each pairwise
comparison using standard GRADE for publication bias; we will
use contour-enhanced funnel plots where appropriate (where
there are 10 or more studies). We will use the contributions
matrix to translate these judgements to the network as a whole.
The CINeMA web tool assesses network meta-analysis evidence
based on the five GRADE domains listed above and downgrades
pairwise, mixed and indirect evidence depending on whether there
are major, some or no concerns.
'Summary of findings' table
For the top five interventions, we plan to present the main
results on response and serious adverse events in 'Summary of
findings' tables, reporting the results for a representative set of
contrasts, with one row for each intervention versus the reference
comparator. These tables will present key information concerning
the certainty of the evidence, the magnitude of the eJects of
the interventions examined, and the sum of the available data
(Schünemann 2019a). 'Summary of findings' tables also include an
overall grading of the evidence using the GRADE approach and will
follow the examples in Yepes-Nuñez 2019.
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A P P E N D I C E S
Appendix 1. Search strategy
Cochrane Central Register of Controlled Trials (CENTRAL) via Ovid Evidence-Based Medicine Reviews Database (EBMR)
1. exp Inflammatory bowel diseases/
2. (Crohn* disease).tw.
3. (inflammatory bowel disease*).tw.




7. (anemia*or anaemia or anemic or anaemic).tw.
8. (iron deficien* or low iron or iron deplet* or hemoglobin or haemoglobin or red blood count or erythropoietin).tw.
9. or/6-8
10. exp Iron/
11. exp Iron Compounds/
12. (iron or ferrous* or ferric* or ferritin or ferumoxytol or sodium feredetate).tw.
13. or/10-12
14. 5 and 9 and 13
MEDLINE (Ovid SP)
1. exp Inflammatory bowel diseases/
2. (Crohn* disease).tw.
3. (inflammatory bowel disease*).tw.




7. (anemia*or anaemia or anemic or anaemic).tw.
8. (iron deficien* or low iron or iron deplet* or hemoglobin or haemoglobin or red blood count or erythropoietin).tw.
9. or/6-8
10. exp Iron/
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11. exp Iron Compounds/
12. (iron or ferrous* or ferric* or ferritin or ferumoxytol or sodium feredetate).tw.
13. or/10-12
14. 5 and 9 and 13
[15-25: Cochrane Handbook RCT filter - sensitivity max version]
15. randomized controlled trial.pt.








24. exp animals/ not humans/
25. 23 not 24
26. 14 and 25
CINAHL (EBSCO)
S1. MH "Inflammatory bowel diseases+"
S2. TI ("Crohn* disease" OR "inflammatory bowel disease" OR "regional enteritis" OR ileitis OR colitis OR proctosigmoiditis OR rectocolitis
OR rectosigmoiditis OR "ulcerative proctocolitis" OR "h#emorrhagic proctocolitis" OR proctitis)
S3. AB ("Crohn* disease" OR "inflammatory bowel disease" OR "regional enteritis" OR ileitis OR colitis OR proctosigmoiditis OR rectocolitis
OR rectosigmoiditis OR "ulcerative proctocolitis" OR "h#emorrhagic proctocolitis" OR proctitis)
S4. S1 OR S2 OR S3
S5. MH "Anemia, Iron-Deficiency"
S6. TI (anemia* OR anaemia OR anemic OR anaemic OR "iron deficien*" OR "low iron" OR "iron deplet*" OR hemoglobin OR haemoglobin
OR "red blood count" OR erythropoietin)
S7. AB (anemia* OR anaemia OR anemic OR anaemic OR "iron deficien*" OR "low iron" OR "iron deplet*" OR hemoglobin OR haemoglobin
OR "red blood count" OR erythropoietin)
S8. S5 OR S6 OR S7
S9. MH "Iron+"
S10. MH "Iron Compounds+"
S11. TI (iron OR ferrous* OR ferric* OR ferritin OR ferumoxytol OR sodium feredetate)
S12. S9 OR S10 OR S11
S13. S4 AND S8 AND S12
[S14: Wong 2006 "therapy studies" filter - SDSSGS version]
S14. MH "treatment outcomes+" OR MH "experimental studies+" or random*
S15. S13 AND S14
ClinicalTrials.gov (Expert search)
(inflammatory bowel disease OR Crohn OR Crohn´s OR Crohns OR regional enteritis OR ileitis OR colitis OR proctosigmoiditis OR rectocolitis
OR rectosigmoiditis OR proctocolitis OR proctitis) AND (iron OR ferric OR ferrous OR ferritin OR ferumoxytol OR sodium feredetate)
WHO ICTRP (Standard search)
inflammatory AND bowel AND disease AND iron OR
inflammatory AND bowel AND disease AND ferr* OR
inflammatory AND bowel AND disease AND ferumoxytol OR
inflammatory AND bowel AND disease AND feredetate OR
inflammatory AND bowel AND disease AND anemi* OR
inflammatory AND bowel AND disease AND anaemi* OR
crohn* AND iron OR
crohn* AND ferr* OR
crohn* AND ferumoxytol OR
crohn* AND feredetate OR
crohn* AND anemi* OR
crohn* AND anaemi*
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